Although the CD44+/CD133+ dual-positive phenotype may imply a stem-like feature of the model, further validation studies are necessary to determine whether our atypical meningioma-derived primary cell lines meet the criteria of CSCs and are suitable for studies on cancer stem cell biology. This evidence concerns the gene CD44 and meningioma.